Who
Steven Gillis
Director
Company insider
Files Form 4 as: Director, Takeda Pharmaceutical Company; 10% owner, Boundless Bio; 10% owner, Prime Medicine; 10% owner, Metsera; Director, VBI Vaccines Inc/BC; Director, Leverage Shares 2X Long FIX Daily ETF; Director, Codiak BioSciences; Director, Pulmatrix.
In numbers
- Trades disclosed
- 144
- Buys
- 10
- Sells
- 8
- Bought
- $69.6M
- Sold
- $9.3M
- Companies
- 13
- Companies where not an officer
- 13
- First trade
- 18 Oct 2006
- Last trade
- 1 Jul 2026
- Last filed
- 6 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 2 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| —filed 6 Jul 2026 | TAK Takeda Pharmaceutical Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | $5.7M1,152 at $4,931.20 | filing |
| —filed 6 Jul 2026 | TAK Takeda Pharmaceutical Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | $5.7M1,152 at $4,931.20 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BOLD Boundless Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —16,000 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BOLD Boundless BioBiotechnology | SEC FORM 4 Code M | $16K16,000 at $1.03 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BOLD Boundless BioBiotechnology | SEC FORM 4 Sold | $40K16,000 at $2.49 | filing |
| 1 Jul 2026filed 6 Jul 2026 | TAK Takeda Pharmaceutical CompanyPharmaceuticals | SEC FORM 4 Code A | —3,800 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | TAK Takeda Pharmaceutical Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,319 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | TAK Takeda Pharmaceutical Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,319 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | TAK Takeda Pharmaceutical CompanyPharmaceuticals | SEC FORM 4 Code A | —3,800 at $0.00 | filing |
| 1 Aug 2025filed 1 Aug 2025 | PRME Prime MedicineBiotechnology | SEC FORM 4 Bought | $10.0M3,030,300 at $3.30 | filing |
| 3 Feb 2025filed 3 Feb 2025 | Metseraoption or derivative | SEC FORM 4 Code C | —19,933,333 | filing |
| 3 Feb 2025filed 3 Feb 2025 | Metseraoption or derivative | SEC FORM 4 Code C | —15,000,000 | filing |
| 3 Feb 2025filed 3 Feb 2025 | Metseraoption or derivative | SEC FORM 4 Code C | —2,678,571 | filing |
| 3 Feb 2025filed 3 Feb 2025 | Metseraoption or derivative | SEC FORM 4 Code C | —15,000,000 | filing |
| 3 Feb 2025filed 3 Feb 2025 | Metseraoption or derivative | SEC FORM 4 Code C | —2,678,571 | filing |
| 3 Feb 2025filed 3 Feb 2025 | Metsera | SEC FORM 4 Code C | —16,006,949 | filing |
| 3 Feb 2025filed 3 Feb 2025 | Metsera | SEC FORM 4 Code C | —7,523,682 | filing |
| 3 Feb 2025filed 3 Feb 2025 | Metsera | SEC FORM 4 Bought | $25.8M1,432,224 at $18.00 | filing |
| 3 Feb 2025filed 3 Feb 2025 | Metsera | SEC FORM 4 Bought | $14.2M789,998 at $18.00 | filing |
| 2 Apr 2024filed 4 Apr 2024 | BOLD Boundless Biooption or derivative · Biotechnology | SEC FORM 4 Code C | —424,908 | filing |
News
No headline names them, or the companies they trade most, lately.